

Tuba N Gide

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8365293/publications.pdf>

Version: 2024-02-01

11
papers

2,037
citations

933264

10
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

4249
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	7.7	547
2	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
3	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	3.2	297
4	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289
5	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	3.2	249
6	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	2.9	150
7	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncotmmunology</i> , 2020, 9, 1659093.	2.1	62
8	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncotmmunology</i> , 2019, 8, e1537581.	2.1	61
9	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828.	1.6	16
10	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 + Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	1.7	11
11	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 51-51.	0.8	0